BLAInjectionInjectablePriority Review
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
LOARGYS (pegzilarginase-nbln) by Medica Corp is arg1-d is an inherited metabolic disease characterized by deficiency of the arginase 1 enzyme and associated with the persistent elevation of plasma arginine. Approved for arginase i deficiency, hyperargininemia. First approved in 2026.
Drug data last refreshed 18h ago
Mechanism of Action
ARG1-D is an inherited metabolic disease characterized by deficiency of the arginase 1 enzyme and associated with the persistent elevation of plasma arginine. LOARGYS provides an exogenous source of the deficient human arginase 1 enzyme activity in patients with ARG1-D and reduces plasma arginine…
Indications (2)
Worked on LOARGYS at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.